Logo image of ALMDT.PA

MEDIAN TECHNOLOGIES (ALMDT.PA) Stock Fundamental Analysis

EPA:ALMDT - Euronext Paris - Matif - FR0011049824 - Common Stock - Currency: EUR

2.26  +0.02 (+1.12%)

Fundamental Rating

1

Overall ALMDT gets a fundamental rating of 1 out of 10. We evaluated ALMDT against 12 industry peers in the Health Care Technology industry. ALMDT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ALMDT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALMDT has reported negative net income.
ALMDT had a negative operating cash flow in the past year.
In the past 5 years ALMDT always reported negative net income.
In the past 5 years ALMDT always reported negative operating cash flow.
ALMDT.PA Yearly Net Income VS EBIT VS OCF VS FCFALMDT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

ALMDT has a worse Return On Assets (-77.03%) than 75.00% of its industry peers.
Industry RankSector Rank
ROA -77.03%
ROE N/A
ROIC N/A
ROA(3y)-53.73%
ROA(5y)-52.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMDT.PA Yearly ROA, ROE, ROICALMDT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600

1.3 Margins

ALMDT has a Gross Margin of 105.00%. This is amongst the best in the industry. ALMDT outperforms 100.00% of its industry peers.
ALMDT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ALMDT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 105%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.82%
GM growth 5Y1.31%
ALMDT.PA Yearly Profit, Operating, Gross MarginsALMDT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

More info and screens

0

2. Health

2.1 Basic Checks

ALMDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALMDT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALMDT has more shares outstanding
ALMDT has a worse debt/assets ratio than last year.
ALMDT.PA Yearly Shares OutstandingALMDT.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ALMDT.PA Yearly Total Debt VS Total AssetsALMDT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -6.97, we must say that ALMDT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ALMDT (-6.97) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.97
ROIC/WACCN/A
WACC6.67%
ALMDT.PA Yearly LT Debt VS Equity VS FCFALMDT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

ALMDT has a Current Ratio of 0.69. This is a bad value and indicates that ALMDT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.69, ALMDT is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
A Quick Ratio of 0.69 indicates that ALMDT may have some problems paying its short term obligations.
The Quick ratio of ALMDT (0.69) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.69
Quick Ratio 0.69
ALMDT.PA Yearly Current Assets VS Current LiabilitesALMDT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

ALMDT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.86%.
The Revenue has decreased by -1.96% in the past year.
The Revenue has been growing by 28.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.96%
Revenue 1Y (TTM)-1.96%
Revenue growth 3Y18.14%
Revenue growth 5Y28.52%
Sales Q2Q%-3.45%

3.2 Future

Based on estimates for the next years, ALMDT will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.73% on average per year.
Based on estimates for the next years, ALMDT will show a quite strong growth in Revenue. The Revenue will grow by 15.24% on average per year.
EPS Next Y6.45%
EPS Next 2Y13.17%
EPS Next 3Y18.73%
EPS Next 5YN/A
Revenue Next Year-11.35%
Revenue Next 2Y4.03%
Revenue Next 3Y15.24%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALMDT.PA Yearly Revenue VS EstimatesALMDT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
ALMDT.PA Yearly EPS VS EstimatesALMDT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALMDT. In the last year negative earnings were reported.
Also next year ALMDT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMDT.PA Price Earnings VS Forward Price EarningsALMDT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMDT.PA Per share dataALMDT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALMDT's earnings are expected to grow with 18.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.17%
EPS Next 3Y18.73%

More info and screens

0

5. Dividend

5.1 Amount

ALMDT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIAN TECHNOLOGIES

EPA:ALMDT (5/22/2025, 7:00:00 PM)

2.26

+0.02 (+1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)10-22 2025-10-22
Inst Owners19.33%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap42.94M
Analysts85.45
Price Target17.07 (655.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.6%
PT rev (3m)0.6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-8.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.97
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS1.15
BVpS-1.15
TBVpS-1.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 105%
FCFM N/A
ROA(3y)-53.73%
ROA(5y)-52.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.82%
GM growth 5Y1.31%
F-Score3
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.23%
Cap/Sales 6.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.69
Quick Ratio 0.69
Altman-Z -6.97
F-Score3
WACC6.67%
ROIC/WACCN/A
Cap/Depr(3y)107.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.67%
Cap/Sales(5y)3.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.96%
EPS Next Y6.45%
EPS Next 2Y13.17%
EPS Next 3Y18.73%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.96%
Revenue growth 3Y18.14%
Revenue growth 5Y28.52%
Sales Q2Q%-3.45%
Revenue Next Year-11.35%
Revenue Next 2Y4.03%
Revenue Next 3Y15.24%
Revenue Next 5YN/A
EBIT growth 1Y-7.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.97%
EBIT Next 3Y15.04%
EBIT Next 5YN/A
FCF growth 1Y-39.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.62%
OCF growth 3YN/A
OCF growth 5YN/A